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Motor Predictors QOL PD
Abstract: The emphasis of treatment for patients with Parkinson disease (PD) is increasingly
concerned with the impact on health related quality of life (HRQOL). Our objective was to
compare the relative value of elements of the motor system in predicting the physical mobility
domain of HRQOL in order to specify targets for intervention. The Parkinson’s Disease
Questionnaire-39 (PDQ-39) was used to assess HRQOL in 263 subjects with PD (H&Y 2.35 +
0.7). A battery of tests assessing demographics, motor impairments and physical function were
administered including the MDS-UPDRS, 10-meter walk test, 6-minute walk test, Freezing of
Gait Questionnaire, Timed Up & Go, Functional Gait Assessment, Berg Balance Test,
Functional Reach and 9- Hole Peg Test. The results of the hierarchical regression analysis
revealed that demographic factors accounted for 33% of the variance in PDQ-39mobility score.
When motor impairments were added to the model, the bradykinesia composite score contributed
a small but significant portion of the variance (R2 change = 0.04, p<0.001). The tremor and
rigidity composite scores did not contribute significantly. The Freezing of Gait Questionnaire
was the strongest predictor (R2 change = 0.20, p<0.001) of the physical function tests followed
by Functional Gait Assessment (R2 change = 0.06, p<0.001) and 6-minute walk test (R2 change =
0.01, p=0.01) accounting for 61% of the variance in PDQ-39mobility score and 44.5% of the more
global PDQ-39total score. These results suggest greater value of physical function tests, and not
tests of motor impairments, in predicting HRQOL. Targeting mobility limitations is an
important consideration.
Key words: Quality of life, Parkinson disease, motor, mobility
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Introduction:
Measures of health related quality of life (HRQOL) and related concepts are increasingly used as
outcome indicators in both research and in clinical practice for patients with neurological
disorders.1 For individuals with Parkinson’s disease (PD), the emphasis of treatment has shifted
from one concerned primarily with ameliorating impairments of the motor system to one that
also considers the impact of the disease state on HRQOL. To date; however, clinical measures
that strongly predict HRQOL in PD remain unclear. Identifying predictors of HRQOL is
necessary in order to target intervention most effectively.
Impairments of the motor system have long been the primary target of pharmacological
interventions. However, an analysis from the DATATOP trial revealed that the Unified
Parkinson Disease Rating Scale (UPDRS) items reflecting severity of impairments of the motor
system (e.g., bradykinesia, rigidity, tremor) were not significant predictors of decline in quality
of life.2 In contrast, several studies have identified an association between higher (worse)
UPDRS postural instability gait disorder (PIGD) scores and poorer HRQOL.2-4 This suggests a
stronger relationship may exist between HRQOL and functional mobility (i.e., gait and postural
control) than between HRQOL and motor impairments.
Given that the mobility items related to postural instability and gait limitations appear to be most
related to HRQOL – other measures of mobility and physical function may provide additional
predictive value and should be considered. Despite their common use and well-accepted clinical
value, UPDRS items are limited in scope. PIGD items, for example, generally focus on the
presence or absence of gait impairment, freezing, postural control using an external perturbation,
use of a walking aid or physical assistance of another person. These items do not consider other
important functional considerations such as walking speed, endurance, obstacle negotiation or
performance during other more complex walking and balance tasks.
Clinical physical function measures, in contrast, provide a relatively more comprehensive
assessment of gait and balance limitations. Many valid and reliable tests of physical
performance are available and include tests of walking (e.g., 10 meter walk test, 6 minute walk
test, Freezing of Gait Questionnaire), postural control (e.g., Berg Balance Test, Functional Gait
Assessment, Functional Reach), transitional movements (e.g., Timed Up & Go) and upper
extremity function (e.g., 9 hole peg test). Although these tests are commonly used by PDfocused researchers and clinicians, the extent to which they may provide value – either
independently or in addition to the PIGD score - in predicting HRQOL has not been investigated.
The purpose of this study was to identify factors that strongly predict HRQOL in PD. Our
specific objective was to expand on previous work by directly comparing three groups of
relevant factors. The groups were: demographic factors, motor system impairments measured by
the gold standard UPDRS, and physical function factors. In particular, we sought to compare the
ability of each factor to predict the perception of HRQOL as reflected in the mobility domain of
the PDQ-39 (PDQ-39mobility). The PDQ-39mobility was targeted in this study to hone in on the
relationship between motor impairments, physical function limitations and perceived health
related to the physical domain of HRQOL. Based on previous research,2-4 we hypothesized that
measures of mobility - and not measures of motor impairment - would predict significance
portions of the variance in the PDQ-39mobility score. In addition, we hypothesized that other
measures of gait and balance - beyond the PIGD score – would significantly predict PDQ39mobility score.
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PATIENTS AND METHODS:
Study Population:
A cross-sectional analysis was conducted on two-hundred and twenty individuals with PD who
were participating in a larger longitudinal study. Subjects were recruited from Movement
Disorders clinics and local support groups at Boston University, University of Utah, Washington
University and University of Alabama. Inclusion criteria included: a diagnosis of idiopathic PD
according to the UK Brain Bank Criteria, modified Hoehn and Yahr stages I-IV, age > 40 years,
living in the community (not institutionalized), able to attend assessment sessions and provide
consent. Subjects were excluded if they had a diagnosis of atypical Parkinsonism, H&Y stage 5
or had previous surgical management of their PD. This study was approved by the Intuitional
Review Boards of all 4 institutions. All subjects who participated in the study provided informed
consent following initial screening.
Study Design:
Subjects participated in an examination in an outpatient clinic over a 2.5 hour period. Timing of
testing was standardized in that all subjects were tested on medication. The following measures
were administered as part of a larger battery of tests: (1) Parkinson’s Disease Questionaire -39
(PDQ-39), (2) Unified Parkinson Disease Rating Scale (MDS-UPDRS) (3) Freezing of Gait
Questionnaire (FOG-Q-Q); (4) Nine Hole Peg Test (9HPT), (5) Berg Balance Test (BBT), (6)
Functional Reach (FR), (7) Functional Gait Assessment (FGA), (8) Timed Up & Go (TUG), (9)
Ten Meter Walk Test (10MWT), (10) Six Minute Walk Test (6MWT). Measures were selected
based on their common use in PD clinical settings and strong psychometric properties.
Evaluators across sites were trained in the standardized implementation of each test using
instructional videos.
Measures:
Parkinson’s Disease Questionnaire-39 (PDQ-39):
The PDQ-39 has been described as a HRQOL instrument that measures health status or
perceived health in terms of physical, mental and social functions.1, 5 The scale has 39 items
made up of 8 subscales: mobility (10 items), activities of daily living (6 items), emotional wellbeing (6 items), stigma (4 items), social support (3 items), cognition (4 items), communication (3
items) and bodily discomfort (3 items). Each item contains a 5-point Likert scale with response
categories ranging from never to always. Scores range from 0-100 with higher scores reflecting a
lower health related quality of life. The mobility domain (PDQ-39mobility) contains items
concerning the frequency in which patients have difficulty getting around the household and
community and participate in chores and leisure activities.
The PDQ-39 was self-administered by each subject. In the event a subject required assistance to
complete the questionnaire, the item was read to the participant and the response was recorded.
An index score was calculated for PDQ-39mobility and for the total scale PDQ-39total.6 Adequate
internal consistency, test–retest reliability, and responsivity have been demonstrated in both the
total and motor subscale score.7, 8 Given the emphasis in this study on predicting HRQOL related
to the physical domain, the mobility subscale score of the PDQ-39 served as the primary
dependent variable. Once significant predictors of the mobility subscale were identified, their
value in predicting the PDQ-39 total score was investigated.
Demographic Factors:
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Demographic and disease specific factors typically gathered in a clinical setting of patients with
PD were collected. These included age, gender, disease duration and disease severity. Disease
severity was measured with the widely utilized modified Hoehn and Yahr Scale (H&Y).9
Motor Impairment Factors:
Unified Parkinson Disease Rating Scale (UPDRS):
The Movement Disorder Society (MDS) revised version of the UPDRS was used in this study.
Validity and high internal consistency have been demonstrated.10 Part II (motor experiences of
daily living) was self-administered by all subjects and part III (motor examination) was
administered by trained investigators. For the analysis, composite scores for the following areas
were established: 1) bradykinesia (left and right finger taps, hand movements, pronationsupination, heel-taps, leg agility and body bradykinesia), 2) rigidity (left and right arms, left and
right legs, neck) and 3) tremor (left and right resting, postural, kinetic).11
Physical Function Factors:
Postural Instability and Gait (PIGD) items of the UPDRS:
The PIGD items of the MDS UPDRS consisted of the walking / balance and freezing items of
part II and the gait, freezing of gait and postural instability items of part III. 11
The 10 meter walk test (10MWT):
The 10MWT is a test used to measure the time it takes for subjects to walk 10 meters at
maximum speed. Validity, high test-retest reliability and responsiveness have been established
in patients with a variety of neurological disorders including those with PD.12, 13
The Six Minute Walk Test: (6MWT):
The 6MWT is a test used to measure the distance subjects can walk in 6-minutes. Subjects were
instructed to walk for six minutes covering as much ground as possible. Validity and high testretest reliability have been demonstrated in patients with cardiopulmonary disease and in patients
with neurological diseases including those with PD.14-16
The Freezing of Gait Questionnaire (FOG-Q):
The FOG-Q is a valid and reliable 6-item survey tool used to assess the severity of freezing of
gait in patients with PD.17 Each item is rated on a 5-point (0-4) ordinal scale with the total score
(sum of 6 items) ranging from 0 (absence of symptom) to 24 (most severe symptom). The FOGQ was self-administered by all subjects in this study.
Functional Gait Assessment (FGA):
The FGA is a 10-item standardized test for assessing postural stability during various walking
tasks. Items include tasks such as walking with head turns, eyes closed, while altering gait speed
and in a backward direction, negotiating obstacles, narrowing base of support, stopping, turning
and stair climbing. Items are scored using a 4-point ordinal scale (0-3) and scores range from 0
to 30 with lower scores indicating more impaired performance. Reliability, internal consistency
and validity have been established.18, 19
Berg Balance Test (BBS):
The BBS is a 14-item scale that quantitatively assesses balance and risk for falls through direct
observation of performance.20 This scale requires approximately 15 minutes to complete and
measures the subject’s ability to maintain balance either statically or dynamically over a
specified period of time.21 The items are scored on a 5 point (0-4) ordinal scale. The total score
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ranges from 0 to 56 with higher scores indicating better balance. Validity and high test-retest
reliability has been demonstrated.15, 22
Functional Reach Test (FR):
The FR is a test used to measure the maximum distance subjects can reach in the forward
direction while their base of support remains fixed.23 The mean of these 3 trials was used in the
analysis. Validity and high test-retest reliability have been established.15, 23
Timed Up & Go (TUG):
The TUG is a test used to measure the time it takes for subjects to rise from a chair, walk 3
meters, turn, walk back and sit down again. Each subject performed 2 trials and the mean time
was used in the analysis. Validity, high test-retest reliability and responsiveness have been
established.13, 24
Nine Hole Peg Test (9HPT):
The 9HPT is a timed measure of fine dexterity and involves placing and removing nine pegs in a
pegboard.25 The mean time of 2 trails using the non-dominant hand was used in this analysis.
Validity and reliability have been established and responsiveness to change demonstrated in
patients with PD.26, 27
Statistical Analysis:
Means + standard deviations (SD) were calculated for all dependent and independent variables.
Pearson and Spearman correlation coefficients were conducted to examine the strength of
association between the PDQ-39mobility and demographic variables, variables representing the
motor impairments and the physical functions measures. Results were similar between Pearson
and Spearman; therefore only Pearson correlation coefficients are presented. Those variables
found to correlate significantly (p<.05) with the PDQ-39mobility were entered into a hierarchical
regression model.
With the PDQ-39mobility score as the dependent variable, independent variables were entered
systematically as three separate blocks into a hierarchical regression analysis. The order of block
entry was determined according to the following clinical rationale: demographic variables (block
1) were entered first based on their non-modifiability; the motor impairment variables (block 2)
were entered next based on their widespread traditional use and potential to respond to
pharmacologic intervention; physical function variables (block 3), because of their potential to
identify targets for rehabilitation intervention, were entered last to assess their predictive value
above and beyond the preceding factors.
Within each block, variables were entered in stepwise fashion. Using an F test ( = 0.05), the
significance of the R2 and R2 change values was examined to identify the strongest predictors of
the PDQ-39mobility score. Those variables found to predict significant portions of the PDQ39mobility score were then entered into a regression model with the PDQ-39total score as the
dependent variable to further assess the predictive value of these mobility tests on overall quality
of life. All data were analyzed using the statistical software program SPSS 16.0.
Results:
Two-hundred and sixty-three subjects with PD participated in this study. Characteristics of the
sample are presented in Table 1. The mean age was 67.7 (9.2), H&Y 2.35 (.69), disease duration
6.2 (4.8) and 57% were male. The mean PDQ-39mobility score was 24.2 (22.8) and the mean
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PDQ-39total score was 21.3 (13.4). Significant correlations were found between the PDQ39mobility score and all independent variables with the exception of sex (Tables 2 & 3). Older age,
longer disease duration and worse disease severity were significantly correlated with poorer
PDQ-39mobility scores with magnitudes ranging from .24 to .51. Poorer scores on the tremor,
rigidity and bradykinesia composite scores were significantly correlated to poorer PDQ-39mobility
scores with magnitudes ranging from .19 to .49. A poorer performance on the PIGD, FOG-Q,
9HPT, FR, BBS, FGA, TUG, 10MWT and 6MWT was significantly correlated to poorer PDQ39mobility scores with magnitudes ranging from .30 to .72.
The results of the hierarchical regression analysis to predict PDQ-39mobility scores are presented in
Table 4. Demographic factors (block 1) accounted for 33% of the variance in PDQ-39mobility
score. The modified H&Y was the strongest predictor of the demographic variables (R2 =0.26,
p<0.001) followed by disease duration (R2 change = 0.06, p<0.001) (Table 4, Model 1). When
the motor impairment factors (block 2) were added to the model, the bradykinesia composite
score contributed a small but significant portion of the variance in PDQ-39mobility score (R2
change = 0.04, p<0.001). The tremor and rigidity composite scores did not contribute
significantly to the model. (Table 4, Model 2). Three of the nine physical function test scores
(block 3) significantly contributed to the model (Table 4, Model 3) with the FOG-Q score as the
strongest predictor (R2 change = 0.20, p<0.001) followed by the FGA score (R2 change = 0.06,
p<0.001) and the 6MWT distance (R2 change = 0.01, p=0.01). Collectively, those variables from
each block that contributed significantly to the model accounted for 61% of the variance in PDQ39mobility score and 44.5% of the more global PDQ-39total score.
Discussion:
Our objective was to expand upon previous research by comparing the relative predictive value
of various factors, both newly and previously identified, for predicting HRQOL in PD.
Specifically, we sought to identify potential targets for an optimal intervention strategy geared
toward improving quality of life.
Our analysis was based on an a priori clinical rationale that recognized both the unmodifiability
of certain demographic factors (e.g., age and duration of disease), the longstanding clinical focus
on motor impairments (e.g., bradykinesia or tremor) as targets of pharmacological intervention
and the potential importance of physical function factors in predicting HRQOL. Accordingly,
the analysis revealed that demographic factors uniquely predicted the greatest portion of variance
(33%) in mobility-related quality of life; UPDRS indicators of motor impairments uniquely
predicted less than 1%, and physical function measures of mobility and postural control uniquely
predicted a final 24%. After taking demographic factors into account, measures of physical
mobility appeared to be stronger predictors of mobility-related quality of life than did the motor
impairment indicators, supporting our initial hypothesis.
The results of this study are consistent with the results of previous studies.2-4 Motor impairments,
such as tremor and rigidity, did not predict the PDQ-39 mobility score which suggests a weak
relationship between the motor impairments associated with PD and quality of life related to
mobility. Some studies also found that bradykinesia was not a significant predictor of quality of
life.28 However, bradykinesia did account for a significant but very small portion of the
variability in HRQOL related to physical mobility, consistent with the results of Muslimovic and
colleagues.3 The result lends further support to the idea that pharmacological interventions
targeting motor impairments, especially when used in isolation, may be unlikely to have a
significant impact on mobility-related quality of life.
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Our findings suggest the relative importance of physical mobility limitations on HRQOL. The
value of additional clinical measures of mobility, particularly the FOG-Q and the FGA, are
evident. This suggests that the severity and nature of freezing episodes in addition to postural
control in the context of more advanced gait activities are more strongly related to HRQOL
compared to tremor and rigidity. In this study, the PIGD composite score did not significantly
contribute to the variance in mobility related quality of life. However, the PIGD score was
highly correlated with the FOG-Q score. A secondary analysis removing the FOG-Q variable
from the analysis revealed that the PIGD score contributed significantly to the model (17%
compared to 20% from the FOG-Q) with the FGA continuing as the second largest contributor.
This provides additional evidence suggesting the greater value of measures of gait and balance in
predicting HRQOL.
These physical function measures are generally easily administered in a clinical environment.
The advantage of the FOG-Q is that it contains only 6-items, is self-administered and takes less
than 5 minutes to complete. On the other hand, it may not adequately capture mobility
limitations in those patients who do not experience gait freezing episodes. The FGA provides a
broader assessment of gait and balance limitations which may help the clinician / researcher to
hone in even further regarding the specific nature of the gait/balance limitation. Difficulties with
walking speed, turning, changing directions, negotiating obstacles and assuming a narrow base
of support can be observed and potentially targeted more specifically in treatment. However, the
FGA requires more space to administer (20 feet and access to stairs) and takes about 10 minutes
to complete. The advantage of using the PIGD composite score is that multiple aspects of
mobility are captured (i.e., gait, postural control and freezing related to gait) providing a
sampling across several potentially important mobility limitations. In addition, information from
both self-report and performance based items are included which may substantiate the findings
as input from both the patient and examiner are considered. The disadvantage of using items
within the UPDRS is the training necessary to administer the motor section. In addition, the
items within the PIGD are scored using a narrow ordinal providing little information as to the
nature of the freezing or postural control deficits.
The relative greater value of measures of gait and balance compared to measures of motor
impairments such as rigidity and tremor in predicting quality of life suggests that treatment
targeted toward these aspects of mobility should be considered. Shulman and colleagues
recently highlighted the pivotal role of gait and balance in daily function and suggested that
difficulty with ambulation should be considered a clinical “red flag” that indicates emerging
disability.29 Although pharmacological treatment is generally effective in ameliorating the motor
symptoms associated with PD, it is less effective in treating gait and postural control deficits. In
contrast, there is evidence to support the effectiveness of physical therapy interventions in
improving aspects of gait and postural control.30, 31 treadmill training,32 use of external cues,33
strengthening exercises,34 and balance training,35, 36 have been demonstrated to improve gait,
balance, freezing and quality of life37 in patients with PD and should be considered for those
with mild to moderate disease severity. Addressing emerging gait and postural control deficits
may help to delay disability and optimize quality of life.
The strengths of this study include the relatively large sample size, participation of subjects
across four different sites and training to ensure a standardized approach to administering
outcome measures across these sites. These factors enhance the generalizability of our findings.
This study is one of the few to investigate the relationship between several widely used measures
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of gait and balance and HRQOL. The results underscore those with the greatest predictive value
helping to guide selection of outcome measures by clinicians and researchers. When considering
the significant contributors within all three variable groups (i.e., demographics, motor
impairment and physical function measures), the hierarchical model accounted for 61% of the
variance in PDQ-39mobility score. Although no previous studies exist with which to compare, we
believe that the combination of factors included in the study may represent the majority of
significant mobility related HRQOL predictors in PD.
Limitations of the study include the cross-sectional nature of the analysis. Therefore, inferences
about factors that predict changes in quality of life over time can not be made. Although
collectively the variables entered into the regression model accounted for 61% of the variability
in the PDQ-39 mobility subscore, 39% remains unaccounted for suggesting the importance of
identifying other relevant factors. Depression, anxiety, insomnia and mood have been shown to
impact overall HRQOL.38-40 It is conceivable that these factors could also impact the physical
domain of HRQOL. Results from the DATATOP trial demonstrated an association between
changes in PIGD score and changes in both mental and physical HRQOL.2 Other possible
limitations of this study include the potential overlap between measures of functional mobility
and the items in the physical domain of the PDQ-39. For example, items # 4 and # 5 of the
PDQ-39 physical mobility domain inquire about difficulties with walking ½ mile and 100 yards
respectively. However, the strength of the correlations between the PDQ-39mobility score and
items directly measuring walking (6MWT, 10MWT, TUG) were similar to the strength of the
correlations between the upper extremity function item (9HPT) and balance tests (BBS, FGA).
In addition, only one walking measure (6MWT) was retained in the final model and it
contributed less than 1% to the variability in the PDQ-39mobility score. It appears that the more
complex mobility tests measuring more than one construct – fluid walking without hesitation
while maintaining postural control – more strongly impact the real-life mobility experiences of
patients in the home and in the community.
In summary, performance on physical function tests of gait and postural control predicted
significant portions of the variance in both the PDQ-39mobility score and the PDQ-39total score,
suggesting the value of physical function tests in predicting HRQOL. Tests of motor
impairments associated with PD were not significant predictors of HRQOL. This suggests that
the severity of the motor impairments is less important to HRQOL than the functional limitations
that result. The combination of the FOG-Q and the FGA were the strongest predictors of the
PDQ-39mobility score when compared to other tests of functional mobility. Targeting mobility
limitations in the treatment of patients with PD is an important consideration in the management
of people with PD.
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Motor Predictors QOL PD
Table 1: Subject Characteristics
Characteristic

Mean (SD) / Total # (%)

Range

Age (years)
Sex (males)
Disease duration (years)
Hoehn & Yahr Stage

67.7 (9.2)
150 (57%)
6.22 (4.8)
2.35 (.69)

40-88

Tremor composite score
Rigidity composite score
PIGD composite score
Bradykinesia composite score

4.5 (4.5)
7.1 (4.0)
4.3 (3.6)
15.3 (8.0)

0-30
0-18
0-18
1-40

Freezing of Gait Questionnaire
9 Hole Peg Test (sec)
Berg Balance Test
Functional Reach (cm)
Functional Gait Assessment

6.0 (5.4)
32.2 (12.4)
50.2 (6.8)
28.0 (8.5)
20.5 (6.4)

0-20
17.8-99.6
14-56
6.0-52.3
0-30

Timed Up & Go (sec)
10 meter walk test (maximum speed)
6 minute walk test (meters)

13.2 (18.5)
6.9 (3.5)
383.1 (157.0)

5.1-219.0
3.1-50.0
29-744

PDQ – 39 Motor Subscale Score
PDQ – 39 Total Score

24.2 (22.8)
21.3 (13.4)

0-92.5
.52-63.1

<1-25
1-4

Motor Predictors QOL PD

Motor Predictors QOL PD

Motor Predictors QOL PD

